Share This Page
Drug Sales Trends for HARVONI
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for HARVONI
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| HARVONI | ⤷ Subscribe | ⤷ Subscribe | 2021 |
| HARVONI | ⤷ Subscribe | ⤷ Subscribe | 2020 |
| HARVONI | ⤷ Subscribe | ⤷ Subscribe | 2019 |
| HARVONI | ⤷ Subscribe | ⤷ Subscribe | 2018 |
| HARVONI | ⤷ Subscribe | ⤷ Subscribe | 2017 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
HARVONI Market Analysis and Financial Projection
Market Analysis and Sales Projections for Harvoni
Overview of Harvoni
Harvoni, a drug developed by Gilead Sciences, is a combination of ledipasvir and sofosbuvir, primarily used to treat hepatitis C virus (HCV) infections. It is indicated for patients with genotype 1 infection, including those with decompensated cirrhosis, and for liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin[1].
Initial Market Success
When Harvoni was first introduced, along with its precursor Sovaldi, it rapidly dominated the hepatitis C market. The drugs' success propelled Gilead Sciences to the top of the HCV treatment sector in 2014 and 2015. During this period, Harvoni and Sovaldi combined accounted for over half of Gilead's product revenue[2].
Decline in Sales
However, the sales of Harvoni began to decline significantly after the initial surge. By the second quarter of 2016, Harvoni's sales had dropped to $2.5 billion, down from $3.6 billion in the same period the previous year. This decline was largely attributed to the maturation of the hepatitis C market and a reduction in the number of new patients starting sofosbuvir-based regimens. In the U.S., the number of patient initiations decreased from 62,000 to 53,000 over the same quarters[2].
Regional Sales Performance
The decline in U.S. sales was particularly steep, with a nearly 50% drop compared to the previous year. Although Harvoni's approval in Japan added $500 million in sales, it was not enough to offset the decline in U.S. sales. The Japanese market, however, did contribute to the overall revenue, but it was insufficient to reverse the downward trend[2].
Market Maturity and Patient Severity
The decline in sales was also linked to the changing demographics of treated patients. As more severely ill patients were treated in the initial years, the remaining patient pool consisted of less severely ill individuals. By 2016, only 13% of patients starting treatment had F4 fibrosis scores, down from over 20% the previous year. This shift in patient severity contributed to the slower rate of new treatments[2].
Competitive Landscape
The hepatitis C market has become increasingly competitive with the entry of other drugs. For example, Merck's Zepatier, which lists for $54,600 per treatment course, posed a challenge to Harvoni and Sovaldi, especially in public sector markets like the Department of Veteran Affairs. Gilead also faced competition from its own newer drug, Epclusa, which is approved for all genotypes of HCV and showed promising sales despite its recent approval[2].
Sales Projections
By 2018, the combined sales of Harvoni, Sovaldi, Epclusa, and Vosevi were forecasted to be between $3.5 billion and $4 billion, a significant drop from the $9.1 billion recorded in 2017. This represented a decline of about 60% from the peak sales in 2015[5].
Regulatory and Cost Challenges
The high cost of Harvoni remains a significant barrier to market growth. The treatment costs approximately $94,500 for a 12-week course, or around $1,100 per pill. This high cost leads to frequent denials of coverage by insurance providers, further reducing the market size. Stringent regulatory norms also hinder the early approval and commercialization of new drugs, affecting the overall market dynamics[3].
Future Market Trends
Despite the current challenges, the viral hepatitis market, including HCV treatments, is expected to grow at a CAGR of 2.69% from 2024 to 2034. This growth is driven by the increasing adoption of innovative antiviral therapies, such as direct-acting antivirals (DAAs), and the integration of digital health technologies. Gilead Sciences, along with other major pharmaceutical companies, continues to invest heavily in R&D for next-generation therapies, which is expected to sustain market growth[4].
Key Takeaways
- Initial Success: Harvoni dominated the HCV market upon its introduction but saw significant sales declines as the market matured.
- Regional Performance: U.S. sales declined sharply, while international markets like Japan provided some relief but were insufficient to reverse the trend.
- Patient Severity: The shift towards treating less severely ill patients contributed to the slower rate of new treatments.
- Competition: The market is highly competitive, with other drugs like Zepatier and Epclusa impacting Harvoni's sales.
- Sales Projections: Combined sales of Harvoni and other HCV drugs by Gilead are expected to remain lower than peak levels.
- Regulatory and Cost Challenges: High treatment costs and stringent regulatory norms continue to affect market growth.
FAQs
Q: What is Harvoni used for? A: Harvoni is used to treat hepatitis C virus (HCV) infections, particularly for patients with genotype 1 infection, including those with decompensated cirrhosis and liver transplant recipients.
Q: Why did Harvoni's sales decline? A: Harvoni's sales declined due to the maturation of the HCV market, a reduction in new patient initiations, and the treatment of less severely ill patients.
Q: How does Harvoni compare to other HCV treatments in terms of cost? A: Harvoni is one of the more expensive HCV treatments, costing around $94,500 for a 12-week course, compared to other drugs like Zepatier which lists for $54,600 per treatment course.
Q: What are the future growth prospects for the HCV treatment market? A: The HCV treatment market is expected to grow at a CAGR of 2.69% from 2024 to 2034, driven by the adoption of innovative antiviral therapies and digital health technologies.
Q: How does Gilead address the decline in Harvoni sales? A: Gilead has been diversifying its HCV treatment portfolio with drugs like Epclusa and Vosevi and is also focusing on partnerships with public providers to expand its market reach.
Sources
- GlobalData, "Net Present Value Model: Harvoni - GlobalData"
- BioPharma Dive, "Gilead trims guidance as Hepatitis C drug sales slip"
- Persistence Market Research, "Global Hepatitis C Treatment Market"
- BioSpace, "Viral Hepatitis Market Estimated to Reach a CAGR of 2.69% during 2024-2034"
- BioPharma Dive, "Gilead forecasts steep slide in 2018 hepatitis C revenues"
More… ↓
